– Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline... | May 25, 2023

Related Keywords

Germany , Australia , Israel , Hong Kong , Switzerland , Chicago , Illinois , United States , Macau , United Kingdom , Canada , Taiwan , China , New Zealand , German , American , West German , Sebastian Bauer , Jonathan Trent , Suzanne George , Robinl Jones , Matthewl Sherman , Translational Sarcoma Research , Institute Of Cancer Research , Deciphera Pharmaceuticals , German Cancer Consortium , Dana Farber Cancer Institute , Deciphera Pharmaceuticals Inc , University Duisburg , Sarcoma Center , Sylvester Comprehensive Cancer Center , American Society Of Clinical Oncology , Linkedin , Nasdaq , Exchange Commission , Clinical Research , European Union , University Hospital Essen , Head Of Sarcoma Center , German Cancer Center , University Of Miami Health System , Clinical Oncology , Annual Meeting , Executive Vice President , Chief Medical Officer , Consultant Medical Oncologist , Royal Marsden , Cancer Research , Discussion Session , Associate Director , Miami Health System , Associate Division Chief , Response Evaluation Criteria , Solid Tumors , West German Cancer Center , University Duisburg Essen , Rapid Abstract , Private Securities Litigation Reform Act , Quarterly Report , Nc Stock Exchange , News , Information , Press Release , Company , Presents , Poster , N , Verall , Survival , End , Safety , Results , Rom , Intrigue , Second , Analysis , Patients , Without , Mundetectable , Ctdna , T Dcph Us24344t1016 ,